Cornell Pochily Investment Advisors Inc. Acquires 19,609 Shares of Kenvue Inc. $KVUE

Key Points

• Cornell Pochily Investment Advisors Inc. increased its stake in Kenvue Inc. by 144.6% during Q2, acquiring an additional 19,609 shares, bringing its total holdings to 33,173 shares valued at $694,000.
• Kenvue's recent earnings reports showed a slight miss in revenue expectations, with earnings per share of $0.29, beating the consensus estimate, while quarterly revenue declined by 4.0% year-over-year.
• The company announced a quarterly dividend increase to $0.2075 per share, providing a 5.3% yield despite a high dividend payout ratio of 112.16%.

Cornell Pochily Investment Advisors Inc. grew its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 144.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,173 shares of the company's stock after acquiring an additional 19,609 shares during the period. Cornell Pochily Investment Advisors Inc.'s holdings in Kenvue were worth $694,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. raised its position in Kenvue by 4.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock worth $2,545,000 after acquiring an additional 4,034 shares during the period. Renaissance Capital LLC increased its stake in shares of Kenvue by 8.3% in the second quarter. Renaissance Capital LLC now owns 629,177 shares of the company's stock worth $13,169,000 after purchasing an additional 48,267 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of Kenvue by 80.7% in the second quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company's stock worth $758,000 after purchasing an additional 16,164 shares in the last quarter. Arlington Partners LLC purchased a new stake in shares of Kenvue in the second quarter worth $2,110,000. Finally, IFP Advisors Inc increased its stake in shares of Kenvue by 25.3% in the first quarter. IFP Advisors Inc now owns 15,278 shares of the company's stock worth $369,000 after purchasing an additional 3,081 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

KVUE opened at $15.72 on Friday. The stock has a market capitalization of $30.16 billion, a price-to-earnings ratio of 21.24, a PEG ratio of 2.28 and a beta of 0.72. The company has a fifty day moving average of $19.85 and a 200 day moving average of $21.63. Kenvue Inc. has a fifty-two week low of $15.47 and a fifty-two week high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.01. The company had revenue of $3.84 billion during the quarter, compared to analysts' expectations of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. Kenvue's quarterly revenue was down 4.0% on a year-over-year basis. During the same period last year, the company posted $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 5.3%. This is an increase from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. Kenvue's dividend payout ratio (DPR) is 112.16%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of a number of analyst reports. Canaccord Genuity Group reduced their price objective on shares of Kenvue from $29.00 to $26.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Barclays reduced their price objective on shares of Kenvue from $20.00 to $17.00 and set an "equal weight" rating for the company in a research note on Wednesday. Royal Bank Of Canada reduced their price objective on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a research note on Friday, August 8th. Evercore ISI reduced their price objective on shares of Kenvue from $23.00 to $18.00 and set an "in-line" rating for the company in a research note on Tuesday, September 23rd. Finally, Zacks Research raised shares of Kenvue to a "strong sell" rating in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Kenvue has an average rating of "Hold" and an average target price of $22.46.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.